{"filing":{"accession_number":"0001193125-26-397037","cik":"0001785279","ticker":"MGX","company_name":"Metagenomi Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-21","report_date":"2026-09-21","primary_document":"mgx-20260921.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526397037/mgx-20260921.htm"},"events":[{"id":34127,"run_id":31395,"accession_number":"0001193125-26-397037","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This Item 7.01 disclosure furnishes a corporate presentation detailing Metagenomi's gene editing platform, lead program MGX-001 for hemophilia A, preclinical data, development roadmap, and pipeline expansion strategy. The presentation covers material operational and strategic information—including cash runway through Q4 2027, FDA pre-IND meeting completion in December 2025, planned Q4 2026 IND submission, and first-patient-dosed timeline in 2027—that would affect a reasonable investor's assessment of the company's clinical progress and capital adequacy. While the disclosure is operational and strategic rather than a specific event type (not M\u0026A, not a restatement, not an impairment), it constitutes material disclosure of the company's therapeutic development status and near-term milestones.","company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","filing_date":"2026-09-21","form":"8-K","submitted_at":null,"items":[{"id":37780,"accession_number":"0001193125-26-397037","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This Item 7.01 disclosure furnishes a corporate presentation detailing Metagenomi's gene editing platform, lead program MGX-001 for hemophilia A, preclinical data, development roadmap, and pipeline expansion strategy. The presentation covers material operational and strategic information—including cash runway through Q4 2027, FDA pre-IND meeting completion in December 2025, planned Q4 2026 IND submission, and first-patient-dosed timeline in 2027—that would affect a reasonable investor's assessment of the company's clinical progress and capital adequacy. While the disclosure is operational and strategic rather than a specific event type (not M\u0026A, not a restatement, not an impairment), it constitutes material disclosure of the company's therapeutic development status and near-term milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T10:04:07.175076+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37780,"accession_number":"0001193125-26-397037","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This Item 7.01 disclosure furnishes a corporate presentation detailing Metagenomi's gene editing platform, lead program MGX-001 for hemophilia A, preclinical data, development roadmap, and pipeline expansion strategy. The presentation covers material operational and strategic information—including cash runway through Q4 2027, FDA pre-IND meeting completion in December 2025, planned Q4 2026 IND submission, and first-patient-dosed timeline in 2027—that would affect a reasonable investor's assessment of the company's clinical progress and capital adequacy. While the disclosure is operational and strategic rather than a specific event type (not M\u0026A, not a restatement, not an impairment), it constitutes material disclosure of the company's therapeutic development status and near-term milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T10:04:07.175076+00:00","company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","filing_date":"2026-09-21"}]}